Plasminogen activators and matrix metalloproteinases during arterial remodeling

Kardiologiya

Volumn 46, Issue 9, 2006, Pages 47-56

  Plekhanova, O S ^a   Solomatina, M A ^a   Menshikov, M Yu ^a   Bashtrykov, P P ^a   Korshunov, V A ^a   Berk, B S ^a   Tkachuk, V A ^a   Parfyonova, Ye V ^a  

^a NONE

Author keywords

Arterial remodeling; Matrix metalloproteinases; Neointima; Plasminogen activators

Indexed keywords

FIBRINOLYTIC AGENT; MATRIX METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOPLASTY; ANIMAL; ARTICLE; CORONARY ARTERY OBSTRUCTION; DRUG COMBINATION; DRUG EFFECT; INTIMA; MALE; METHODOLOGY; RAT; WISTAR RAT;

ANGIOPLASTY; ANIMALS; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, WISTAR; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA;

EID: 33750202728     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kuntz R.E., Baim D.S. Defining coronary restenosis. New clinical and angiographic paradigms. Circulation 1993;88:1310-1322.
2. Topol E.J., Ellis S. G., Casgrave D.M. et al. Analysis of coronary angioplasty practice in the United States with an insurance-claims database. Circulation 1993;87:1489-1497.
3. Ruygrok P.N., Serrays R.W. Intracoronary stenting: from concept concept to custom. Circulation 1996;94:882-890.
4. Mulvany M.J., Baumbach G.L., Aalkjaer C. et al. Vascular remodeling. Hypertension 1996;28:505-506.
5. Glagov S. lntimalhyperplasia, vascular modeling, and the restenosis problem. Circulation 1994;89:2888-2891.
6. Kakuta T., Currier J.W., Haudenschild C.C. et al. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809-2815.
7. Lange L.A., Bowden D.W., Langefeld C.D. et al. Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke 2002;330:1876-1881.
8. Dangas G., Mintz G.S., Mehran R. et al. Preintervention arterial remodeling as an independent predictor of target-lesion revascularization after nonstent coronary intervention: an analysis of 777 lessions with intravascular ultrasound imaging. Circulation 1999;99:3149-3154.
9. Bots M.L., Hoes A.W., Koudstaal P.J. et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-1437.
10. Clowes A.W., Reidy M.A., Clowes M.M. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-215.
11. Ciezki J.P., Hafeli U.O., Song P. et al. Parenchymal cell proliferation in coronary arteries after percutaneous transluminal coronary angioplasty: a human tissue bank study. Int J Radiat Oncol Biol Phys 1999;45:963-968.
12. Sierevogel M.J., Pasterkamp G., de Kleijn D.P., Strauss B.H. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003;9:1033-1040.
13. Carmeliet P.F. Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. Bail Clin Haematol 1995;8:391-401.
14. Clowes A.W., Clowes M.M., Au Y.P. et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circulat Res 1990;67:61-67.
15. Plekhanova O.S., Parfyonova Ye.V., Bibilashvily R.S. et al. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 2001;159:2:297-306.
16. Parfyonova Ye.V., Plekhanova O.S., Solomatina M.A. et al. Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodeling early after arterial injury. J Vasc Res 2004;41:268-276.
17. Carmeliet P., Moons L., Herbert J.M. et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circulat Res 1997;81:829-839.
18. Falkenberg M., Tom C., DeYoung M.B. et al. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA 2002;99:10665-10670.
19. Strauss B.H., Lau H.K., Bowman K.A. et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-1622.
20. Parfyonova Ye., Alekseeva I., Nasonov E. et al. Cumulative predictive value of plasma urokinase antigen, PAI-1 activity and CRP for late clinical recurrence after coronary stenting. International Congress of the International Society for Fibrinolysis and Proteolysis (ISFP): 16-th: Abstracts 2002;30:26.
21. Araujo C.M., Rando G.A., Mauro M.F. et al. Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study. Arq Bras Cardiol 2005;84:256-260.
22. van Beusekom H.M., Post M.J., Whelan D.M. et al. Metalloproteinase inhibition by batimastat does not reduce neointimal thickening in stented atherosclerotic porcine femoral arteries. Cardiovasc Radiat Med 2003;4:186-191.
23. Korshunov V.A., Berk B.C. Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol 2003;23:2185-2191.
24. Mulvany M.J., Baumbach G.L., Aalkjaer C. et al. Vascular remodeling. Hypertension 1996;28:505-506.
25. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-270.
26. Lijnen H.R., Van Hoef B., Lupu F. et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998;18:1035-1045.
27. Mason D.P., Kenagy R.D., Hasenstab D. et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circulat Res 1999;85:1179-1185.
28. Carmeliet P., Moons L., Dewerchin M.J. et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 1998;140:233-245.
29. Menshikov M., Elizarova E., Plakida K. et al. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 2002;367:Pt 3:833-839.
30. Korshunov V., Solomatina M., Plekhanova O. et al. Strain-dependent expression of proteolytic molecules during vascular remodeling in the mice. J Vasc Res 2004;41:481-490.
31. Plekhanova O.S., Solomatina M.A., Viborov O.A. Oligonucleotide microarrays reveal regulated genes causing opposite vessel remodeling induced by plasminogen activators. International Symposium on Atherosclerosis, 13-th: Abstracts. Atherosclerosis 2003;4:325.